Sitaem Tablet 50/1000 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hallym Pharmaceutical Co., Ltd.
MFDS item code 201505754 · Approved 2015.08.18
This product's status changed to Approval withdrawn on 2025.02.12. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in type 2 diabetes
This medication is used as an adjunct to diet and exercise in helping patients with type 2 diabetes control their blood sugar levels. It is particularly effective for those who have not previously taken diabetes medications or find it difficult to control blood sugar with monotherapy. Additionally, it can be used when adequate blood sugar control is not achieved with monotherapy of Metformin or Sitagliptin, or when it substitutes the combination therapy of the two medications. For patients who are unable to control blood sugar even with the combination therapy of Metformin, sulfonylureas, thiazolidinediones, or insulin, this drug can be administered, improving blood sugar control. This medication plays a role in helping control blood sugar across various treatment stages, making it useful for the management of type 2 diabetes.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medication should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medication is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is used in the treatment of diabetes and may cause serious allergic reactions, so caution is warranted. If symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a doctor. Additionally, there is a risk of pancreatitis (inflammation of the pancreas) with this medication; therefore, symptoms like abdominal pain, vomiting, or nausea should be reported to medical staff promptly. Patients with impaired kidney function, dehydration, severe infection, or heart failure should not take this medication, and should stop taking it immediately if such conditions occur. The medication should be discontinued before tests utilizing contrast agents and should be resumed only after confirming normal kidney function post-examination. It is safer for pregnant or potentially pregnant women and nursing mothers not to use this medication. This drug can cause hypoglycemia, so particular caution should be exercised when combined with irregular meals, intense exercise, or other hypoglycemic medications. Regular testing of kidney function and blood tests should be undertaken, and monitoring of vitamin B12 levels is advisable. Alcohol intake can increase the risk of side effects from this medication, so it should be avoided while taking it. It is recommended to temporarily suspend taking this drug before and after surgery, resuming only after the patient's condition is recovered. During treatment with this medication, prompt reporting to a doctor is necessary in cases of sudden muscle pain, joint pain, skin rash, or blisters. In the case of overdose, immediate medical attention is required for appropriate treatment, and if necessary, blood dialysis may be used to remove the drug. Elderly patients may experience decreased kidney function, so dosage adjustments and regular monitoring of kidney function are recommended. It is important to consult medical staff promptly if there are changes in health status or abnormal symptoms during treatment with this medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air from entering, and it is advisable to keep it at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's efficacy over time.
Dark red oval film-coated tablet
56 tablets (14 tablets/PTP packaging × 4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hallym Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.